Unlocking the Potential of C22orf42: A Potential Drug Target and Biomarker

Target Name: C22orf42

NCBI ID: G150297

C22orf42

Unlocking the Potential of C22orf42: A Potential Drug Target and Biomarker

C22orf42, also known as dJ90G24.6, is a gene located on chromosome 9q34. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This article will delve into the research on C22orf42, its potential drug target status, and its potential as a biomarker for disease.

Potential Drug Target

C22orf42 is a gene that encodes a protein known as D901, which is expressed in various tissues throughout the body. The protein is known to play a crucial role in cell signaling, specifically in the regulation of cell adhesion and migration. D901 has been shown to interact with several protein partners, including the protein p120Gsk, which is a known co-factor for the oncogene B-cell lymphoma 1 (Bcl-2).

Several studies have shown that Bcl-2 is a known drug target for various diseases, including cancer. The p120Gsk-D901 interaction suggests that C22orf42 may also be a potential drug target for cancer. Several small molecules have been shown to interact with D901, and some of these molecules have been shown to have potential therapeutic effects in cancer treatment. For example, the drug inhibitor PD-L1 has been shown to target the Bcl-2 protein and has been shown to have therapeutic effects in various cancers.

Biomarker Potential

C22orf42 has also been identified as a potential biomarker for several diseases, including cancer. The D901 protein has been shown to be expressed in various tissues and has been shown to play a role in the regulation of cell adhesion and migration. This suggests that D901 may be a potential biomarker for diseases that involve these processes, such as cancer.

Several studies have shown that the expression of D901 is significantly increased in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, several studies have shown that the D901 protein is involved in the regulation of cell cycle progression, which is a critical process in cancer development.

Conclusion

In conclusion, C22orf42 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The research on C22orf42 has shown that it plays a crucial role in cell signaling and has been shown to interact with several protein partners, including the oncogene Bcl-2. Additionally, several studies have shown that C22orf42 is involved in the regulation of cell cycle progression, which is a critical process in cancer development. Further research is needed to fully understand the potential of C22orf42 as a drug target and biomarker for various diseases.

Protein Name: Chromosome 22 Open Reading Frame 42

The "C22orf42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C22orf42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets